Clinical and surgical characteristics between the central and peripheral groups
| Characteristicsa . | Central (n = 299) . | Peripheral (n = 941) . | P-value . |
|---|---|---|---|
| Age, years | 70 (64–76) | 69 (62–75) | 0.138 |
| Sex | 0.560 | ||
| Female | 164 (54%) | 498 (53%) | |
| Male | 135 (45%) | 443 (47%) | |
| Smoking history (yes) | 180 (60%) | 581 (62%) | 0.633 |
| Whole tumour size (mm) | 15 (13–17) | 15 (13–18) | 0.169 |
| Solid tumour size (mm) | 14 (11-17) | 14 (11–17) | 0.736 |
| Pure solid tumour | 214 (72%) | 604 (64%) | 0.018 |
| SUVmax | 2.7 (1.4–4.8) | 2.4 (1.3–4.8) | 0.182 |
| Tumour location | 0.679 | ||
| Right upper lobe | 93 (31%) | 303 (32%) | |
| Right middle lobe | 29 (10%) | 70 (7%) | |
| Right lower lobe | 60 (20%) | 211 (22%) | |
| Left upper lobe | 70 (23%) | 206 (22%) | |
| Left lower lobe | 47 (16%) | 151 (16%) | |
| Surgical procedure | 0.105 | ||
| Lobectomy | 178 (60%) | 609 (64%) | |
| Segmentectomy | 121 (40%) | 332 (35%) | |
| Number of resected segments | 0.102 | ||
| 1 | 67 (59%) | 207 (66%) | |
| 2 | 37 (32%) | 98 (31%) | |
| ≥3 | 9 (8%) | 10 (3%) | |
| Surgical margin in segmentectomy (n = 90/n = 235) | 10 (6–17) | 15 (10–25) | <0.001 |
| Number of lymph nodes dissected | 9 (5–16) | 10 (5–17) | 0.490 |
| Histology | 0.055 | ||
| Adenocarcinoma | 238 (80%) | 777 (83%) | |
| Squamous cell carcinoma | 34 (11%) | 115 (12%) | |
| Others | 27 (9%) | 49 (5%) | |
| Pathological T factor | 0.065 | ||
| pT1 | 262 (88%) | 766 (81%) | |
| pT2 | 28 (9%) | 145 (15%) | |
| pT3 | 8 (3%) | 28 (3%) | |
| pT4 (mediastinal fat invasion) | 1 (<1%) | 2 (<1%) | |
| Pathological N factor | 0.038 | ||
| pN0 | 270 (90%) | 872 (93%) | |
| pN1 | 22 (7%) | 37 (4%) | |
| pN2 | 7 (2%) | 32 (3%) | |
| Pleural invasion | 31 (10%) | 147 (16%) | 0.024 |
| Lymphatic invasion | 67 (22%) | 187 (20%) | 0.344 |
| Vascular invasion | 81 (27%) | 228 (24%) | 0.319 |
| EGFR mutation | 0.219 | ||
| Exon 19 del | 17 (6%) | 48 (5%) | |
| Exon 21 L858R | 15 (5%) | 64 (7%) | |
| Uncommon mutation | 5 (2%) | 17 (2%) | |
| Wild type | 29 (10%) | 133 (14%) | |
| Unknown | 233 (78%) | 679 (72%) | |
| ALK fusion | 0.898 | ||
| Positive | 7 (2%) | 18 (2%) | |
| Wild type | 113 (38%) | 359 (38%) | |
| Unknown | 179 (60%) | 564 (60%) | |
| Adjuvant (yes) | 32 (11%) | 107 (11%) | 0.745 |
| Characteristicsa . | Central (n = 299) . | Peripheral (n = 941) . | P-value . |
|---|---|---|---|
| Age, years | 70 (64–76) | 69 (62–75) | 0.138 |
| Sex | 0.560 | ||
| Female | 164 (54%) | 498 (53%) | |
| Male | 135 (45%) | 443 (47%) | |
| Smoking history (yes) | 180 (60%) | 581 (62%) | 0.633 |
| Whole tumour size (mm) | 15 (13–17) | 15 (13–18) | 0.169 |
| Solid tumour size (mm) | 14 (11-17) | 14 (11–17) | 0.736 |
| Pure solid tumour | 214 (72%) | 604 (64%) | 0.018 |
| SUVmax | 2.7 (1.4–4.8) | 2.4 (1.3–4.8) | 0.182 |
| Tumour location | 0.679 | ||
| Right upper lobe | 93 (31%) | 303 (32%) | |
| Right middle lobe | 29 (10%) | 70 (7%) | |
| Right lower lobe | 60 (20%) | 211 (22%) | |
| Left upper lobe | 70 (23%) | 206 (22%) | |
| Left lower lobe | 47 (16%) | 151 (16%) | |
| Surgical procedure | 0.105 | ||
| Lobectomy | 178 (60%) | 609 (64%) | |
| Segmentectomy | 121 (40%) | 332 (35%) | |
| Number of resected segments | 0.102 | ||
| 1 | 67 (59%) | 207 (66%) | |
| 2 | 37 (32%) | 98 (31%) | |
| ≥3 | 9 (8%) | 10 (3%) | |
| Surgical margin in segmentectomy (n = 90/n = 235) | 10 (6–17) | 15 (10–25) | <0.001 |
| Number of lymph nodes dissected | 9 (5–16) | 10 (5–17) | 0.490 |
| Histology | 0.055 | ||
| Adenocarcinoma | 238 (80%) | 777 (83%) | |
| Squamous cell carcinoma | 34 (11%) | 115 (12%) | |
| Others | 27 (9%) | 49 (5%) | |
| Pathological T factor | 0.065 | ||
| pT1 | 262 (88%) | 766 (81%) | |
| pT2 | 28 (9%) | 145 (15%) | |
| pT3 | 8 (3%) | 28 (3%) | |
| pT4 (mediastinal fat invasion) | 1 (<1%) | 2 (<1%) | |
| Pathological N factor | 0.038 | ||
| pN0 | 270 (90%) | 872 (93%) | |
| pN1 | 22 (7%) | 37 (4%) | |
| pN2 | 7 (2%) | 32 (3%) | |
| Pleural invasion | 31 (10%) | 147 (16%) | 0.024 |
| Lymphatic invasion | 67 (22%) | 187 (20%) | 0.344 |
| Vascular invasion | 81 (27%) | 228 (24%) | 0.319 |
| EGFR mutation | 0.219 | ||
| Exon 19 del | 17 (6%) | 48 (5%) | |
| Exon 21 L858R | 15 (5%) | 64 (7%) | |
| Uncommon mutation | 5 (2%) | 17 (2%) | |
| Wild type | 29 (10%) | 133 (14%) | |
| Unknown | 233 (78%) | 679 (72%) | |
| ALK fusion | 0.898 | ||
| Positive | 7 (2%) | 18 (2%) | |
| Wild type | 113 (38%) | 359 (38%) | |
| Unknown | 179 (60%) | 564 (60%) | |
| Adjuvant (yes) | 32 (11%) | 107 (11%) | 0.745 |
Categorical data are expressed as n (%) and continuous data as median (interquartile).
ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; SUVmax: the maximum standardized uptake.
Clinical and surgical characteristics between the central and peripheral groups
| Characteristicsa . | Central (n = 299) . | Peripheral (n = 941) . | P-value . |
|---|---|---|---|
| Age, years | 70 (64–76) | 69 (62–75) | 0.138 |
| Sex | 0.560 | ||
| Female | 164 (54%) | 498 (53%) | |
| Male | 135 (45%) | 443 (47%) | |
| Smoking history (yes) | 180 (60%) | 581 (62%) | 0.633 |
| Whole tumour size (mm) | 15 (13–17) | 15 (13–18) | 0.169 |
| Solid tumour size (mm) | 14 (11-17) | 14 (11–17) | 0.736 |
| Pure solid tumour | 214 (72%) | 604 (64%) | 0.018 |
| SUVmax | 2.7 (1.4–4.8) | 2.4 (1.3–4.8) | 0.182 |
| Tumour location | 0.679 | ||
| Right upper lobe | 93 (31%) | 303 (32%) | |
| Right middle lobe | 29 (10%) | 70 (7%) | |
| Right lower lobe | 60 (20%) | 211 (22%) | |
| Left upper lobe | 70 (23%) | 206 (22%) | |
| Left lower lobe | 47 (16%) | 151 (16%) | |
| Surgical procedure | 0.105 | ||
| Lobectomy | 178 (60%) | 609 (64%) | |
| Segmentectomy | 121 (40%) | 332 (35%) | |
| Number of resected segments | 0.102 | ||
| 1 | 67 (59%) | 207 (66%) | |
| 2 | 37 (32%) | 98 (31%) | |
| ≥3 | 9 (8%) | 10 (3%) | |
| Surgical margin in segmentectomy (n = 90/n = 235) | 10 (6–17) | 15 (10–25) | <0.001 |
| Number of lymph nodes dissected | 9 (5–16) | 10 (5–17) | 0.490 |
| Histology | 0.055 | ||
| Adenocarcinoma | 238 (80%) | 777 (83%) | |
| Squamous cell carcinoma | 34 (11%) | 115 (12%) | |
| Others | 27 (9%) | 49 (5%) | |
| Pathological T factor | 0.065 | ||
| pT1 | 262 (88%) | 766 (81%) | |
| pT2 | 28 (9%) | 145 (15%) | |
| pT3 | 8 (3%) | 28 (3%) | |
| pT4 (mediastinal fat invasion) | 1 (<1%) | 2 (<1%) | |
| Pathological N factor | 0.038 | ||
| pN0 | 270 (90%) | 872 (93%) | |
| pN1 | 22 (7%) | 37 (4%) | |
| pN2 | 7 (2%) | 32 (3%) | |
| Pleural invasion | 31 (10%) | 147 (16%) | 0.024 |
| Lymphatic invasion | 67 (22%) | 187 (20%) | 0.344 |
| Vascular invasion | 81 (27%) | 228 (24%) | 0.319 |
| EGFR mutation | 0.219 | ||
| Exon 19 del | 17 (6%) | 48 (5%) | |
| Exon 21 L858R | 15 (5%) | 64 (7%) | |
| Uncommon mutation | 5 (2%) | 17 (2%) | |
| Wild type | 29 (10%) | 133 (14%) | |
| Unknown | 233 (78%) | 679 (72%) | |
| ALK fusion | 0.898 | ||
| Positive | 7 (2%) | 18 (2%) | |
| Wild type | 113 (38%) | 359 (38%) | |
| Unknown | 179 (60%) | 564 (60%) | |
| Adjuvant (yes) | 32 (11%) | 107 (11%) | 0.745 |
| Characteristicsa . | Central (n = 299) . | Peripheral (n = 941) . | P-value . |
|---|---|---|---|
| Age, years | 70 (64–76) | 69 (62–75) | 0.138 |
| Sex | 0.560 | ||
| Female | 164 (54%) | 498 (53%) | |
| Male | 135 (45%) | 443 (47%) | |
| Smoking history (yes) | 180 (60%) | 581 (62%) | 0.633 |
| Whole tumour size (mm) | 15 (13–17) | 15 (13–18) | 0.169 |
| Solid tumour size (mm) | 14 (11-17) | 14 (11–17) | 0.736 |
| Pure solid tumour | 214 (72%) | 604 (64%) | 0.018 |
| SUVmax | 2.7 (1.4–4.8) | 2.4 (1.3–4.8) | 0.182 |
| Tumour location | 0.679 | ||
| Right upper lobe | 93 (31%) | 303 (32%) | |
| Right middle lobe | 29 (10%) | 70 (7%) | |
| Right lower lobe | 60 (20%) | 211 (22%) | |
| Left upper lobe | 70 (23%) | 206 (22%) | |
| Left lower lobe | 47 (16%) | 151 (16%) | |
| Surgical procedure | 0.105 | ||
| Lobectomy | 178 (60%) | 609 (64%) | |
| Segmentectomy | 121 (40%) | 332 (35%) | |
| Number of resected segments | 0.102 | ||
| 1 | 67 (59%) | 207 (66%) | |
| 2 | 37 (32%) | 98 (31%) | |
| ≥3 | 9 (8%) | 10 (3%) | |
| Surgical margin in segmentectomy (n = 90/n = 235) | 10 (6–17) | 15 (10–25) | <0.001 |
| Number of lymph nodes dissected | 9 (5–16) | 10 (5–17) | 0.490 |
| Histology | 0.055 | ||
| Adenocarcinoma | 238 (80%) | 777 (83%) | |
| Squamous cell carcinoma | 34 (11%) | 115 (12%) | |
| Others | 27 (9%) | 49 (5%) | |
| Pathological T factor | 0.065 | ||
| pT1 | 262 (88%) | 766 (81%) | |
| pT2 | 28 (9%) | 145 (15%) | |
| pT3 | 8 (3%) | 28 (3%) | |
| pT4 (mediastinal fat invasion) | 1 (<1%) | 2 (<1%) | |
| Pathological N factor | 0.038 | ||
| pN0 | 270 (90%) | 872 (93%) | |
| pN1 | 22 (7%) | 37 (4%) | |
| pN2 | 7 (2%) | 32 (3%) | |
| Pleural invasion | 31 (10%) | 147 (16%) | 0.024 |
| Lymphatic invasion | 67 (22%) | 187 (20%) | 0.344 |
| Vascular invasion | 81 (27%) | 228 (24%) | 0.319 |
| EGFR mutation | 0.219 | ||
| Exon 19 del | 17 (6%) | 48 (5%) | |
| Exon 21 L858R | 15 (5%) | 64 (7%) | |
| Uncommon mutation | 5 (2%) | 17 (2%) | |
| Wild type | 29 (10%) | 133 (14%) | |
| Unknown | 233 (78%) | 679 (72%) | |
| ALK fusion | 0.898 | ||
| Positive | 7 (2%) | 18 (2%) | |
| Wild type | 113 (38%) | 359 (38%) | |
| Unknown | 179 (60%) | 564 (60%) | |
| Adjuvant (yes) | 32 (11%) | 107 (11%) | 0.745 |
Categorical data are expressed as n (%) and continuous data as median (interquartile).
ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; SUVmax: the maximum standardized uptake.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
